Systemic treatment of advanced hepatocellular cancer: new hope on the horizon

References

• Mazzoccoli G, Tarquini R, Valoriani A, et al. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med. 2016;16:243–256.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Kelly SP, Altekruse SF, et al. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34:1787–1794.
   PubMed Web of Science ®Google Scholar
• McGlynn A, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–238.
   PubMed Web of Science ®Google Scholar
• Nordensted H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(3):S206–S214.
   PubMedGoogle Scholar
• Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302–309.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancers. Version 3.  J National Comprehensive Cancer Network. 2018. p. 46–71.
   Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699.
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma –an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23(11):1535–1547.
   PubMed Web of Science ®Google Scholar
• Hollebecque A, Malka D, Ferté C, et al. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer. 2015;51:327–339.
   PubMed Web of Science ®Google Scholar
• Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012;18:6005–6017.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Marrero J, Venook A, et al. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract. 2010;64:1034–1041.
   PubMed Web of Science ®Google Scholar
• Marrero J, Lencioni R, Ye SL, et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction. J Clin Oncol. 2013;31(Suppl. 15):4126.
   Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a Phase III trial. J Hepatol. 2012;57:821–829.
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two Phase III studies. J Hepatol. 2017;67:999–1008.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the Phase III sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48:1452–1465.
   PubMed Web of Science ®Google Scholar
• Jackson R, Psarelli EE, Berhane S, et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol. 2017;35:622–628.
   PubMed Web of Science ®Google Scholar
• Reiss KA, Yu S, Mamtani R, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol. 2017;35(31):3575–3581.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–4075.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179.
   PubMed Web of Science ®Google Scholar
• Zhu A, Rosmorduc O, Evans J, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2015;33(6):559–566.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391::1163–1173.
   PubMed Web of Science ®Google Scholar
• Vogel A, Qin S, Kudo M, et al. Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Value Health. 2017;20:A454–A455.
   Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–358.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–534.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36(Suppl. 4)):TPS538–TPS538.
   Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–2998.
   PubMed Web of Science ®Google Scholar
• Fang P, Hu JH, Cheng ZG, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012;7(12):e49717.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Zarrabi K, Wu S. Risk of liver toxicity with nivolumab immunotherapy in cancer patients. Oncology. 2018;94(5):259–273.
   PubMed Web of Science ®Google Scholar
• Sangro B, Park JW, Dela Cruz C, et al. A randomized, multicenter, phase 3 study of nivolumab versus sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): checkmate-459 (abstract). J Clin Oncol. 2016;34(Suppl. 15):TPS4147–TPS4147.
   Google Scholar
• Zhu AX, Finn RS, Cattan S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.
   PubMed Web of Science ®Google Scholar
• Finn RS, Chan SL, Zhu AX, et al. Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240. J Clin Oncol. 2017;35(Suppl. 15):TPS4143–TPS4143.
   Google Scholar
• Pishvaian MJ, Lee MS, Ryoo B, et al. Updated Safety and clinical activity results from a Phase 1b study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018 Congress. LBA 26.
   Google Scholar
• Finn RS, Ducreux M, Qin S, et al. IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol. 2018;36(Suppl. 15):TPS4141–TPS4141.
   Web of Science ®Google Scholar
• Vejchapipat P, Tangkijvanich P, Theamboonlers A, et al. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol. 2004;39(12):1182–1188.
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67:1132–1149.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of advanced MET-high hepatocellular carcinoma (METIV-HCC): a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693.
   PubMed Web of Science ®Google Scholar
• Decaens T, Barone C, Assenat E, et al. Phase 2 efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). Ann Oncol. 2018;29(suppl_8):viii205–viii270.
   Google Scholar
• Lee SS, Miller A, Krishnamurthi SS, et al. Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. J Clin Oncol. 2018;36(Suppl. 4):364.
   Web of Science ®Google Scholar
• Kim R, Sarker D, Macarulla T, et al. Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2017;28:v122–v141.
   Google Scholar
• Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2018;36(suppl; abstr 4076).
   Google Scholar
• Di Costanzo GG, de Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11(6):943–951.
   PubMed Web of Science ®Google Scholar
• Di Costanzo GG, Gardini AS, Marisi G, et al. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Targeted Oncol. 2017;12(6):795–803.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim BK, Kim SU, et al. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma. 2015;2:39–47.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña C, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–2300.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, et al. PDL1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay comparison project. J Thorac Oncol. 2017;12:208–222.
   PubMed Web of Science ®Google Scholar
• Hellman MD, Ciuleanu T, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104.
   PubMed Web of Science ®Google Scholar
• Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011;19(3):347–358.
   PubMed Web of Science ®Google Scholar
• Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60(6):1972–1982.
   PubMed Web of Science ®Google Scholar
• Heo J, Breitbach C, Cho M, et al. Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2013;31(Suppl. 15):4122.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Galle P, Chao Y, et al. PHOCUS: a phase 3 randomized, open-label study comparing the oncolytic immunotherapy pexa vec followed by sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. J Clin Oncol. 2016;34(Suppl. 15):TPS4146–TPS4146.
   Web of Science ®Google Scholar
• Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol. 2017;35(Suppl. 15):4073.
   Google Scholar
• Camisaschi C, Vallacchi V, Vergani E, et al. Targeting immune regulatory networks to counteract immune suppression in cancer. Vaccines (Basel). 2016;4(4):38.
   Web of Science ®Google Scholar
• Bang YJ, Goff LW, Wasserstrom H, et al. An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC). Ann Oncol. 2016;27(6):1100TiP.
   Google Scholar
• Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology. 2017;93:135–146.
   PubMed Web of Science ®Google Scholar
• Tarakanovskaya MG, Chinburen J, Batchuluun P, et al. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma. 2017;4:59–69.
   PubMed Web of Science ®Google Scholar
• Li M, Li H, Li C, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signalling in human hepatoma cell lines. Int J Cancer. 2011;128(3):524–532.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chang-Yong E, Gong ZW, et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018;17(4):301–309.
   PubMed Web of Science ®Google Scholar
• Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(3):220–229.
   PubMed Web of Science ®Google Scholar
• Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65:1031–1042.
   PubMed Web of Science ®Google Scholar
• Liu Z, Guo W, Zhang D, et al. Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry. Sci Rep. 2016;6:39808.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Magbanua MJ, Butler TM, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206.
   PubMed Web of Science ®Google Scholar
• Blanc JF, Khemissa F, Bronowicki JP, et al. Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients. J Hepatol. 2018;68(Suppl. 1):S195.
   Google Scholar
• Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer. 2012;118:5293–5301.
   PubMed Web of Science ®Google Scholar
• Santini D, Addeo R, Vincenzi B, et al. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Rev Anticancer Ther. 2012;12:1283–1288.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Terzi E, Cucchetti A, et al. Treatment of hepatocellular carcinoma in Child-Pugh B patients. Dig Liver Dis. 2013;45(10):852–858.
   PubMedGoogle Scholar
• Kambhampati S, Bauer K, Hwang J, et al. Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: safety and clinical outcomes in a retrospective case series. J Clin Oncol. 2018;36(Suppl. 4):496.
   Web of Science ®Google Scholar